Get the Stockscreener App
34.57
1.54%
-0.54
After Hours:
34.60
0.03
+0.09%
Bridgebio Pharma Inc stock is traded at $34.57, with a volume of 2.49M.
It is down -1.54% in the last 24 hours and down -0.95% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$35.11
Open:
$35.24
24h Volume:
2.49M
Relative Volume:
0.91
Market Cap:
$6.69B
Revenue:
$217.77M
Net Income/Loss:
$-438.86M
P/E Ratio:
-14.34
EPS:
-2.41
Net Cash Flow:
$-456.33M
1W Performance:
-7.12%
1M Performance:
-0.95%
6M Performance:
+35.78%
1Y Performance:
+11.80%
1-Day Range:
$33.85
$35.37
1-Week Range:
$33.85
$37.57
52-Week Range:
$21.62
$39.47
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Compare BBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
34.57 | 6.69B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-03-24 | Initiated | Oppenheimer | Perform |
| Sep-04-24 | Initiated | Piper Sandler | Overweight |
| Mar-21-24 | Resumed | Raymond James | Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
BridgeBio Pharma Says Acoramidis Improves Outcomes in Phase 3 ATTR-CM Trial - MarketScreener
Acoramidis shows promise in ATTR-CM Phase 3 trial - Investing.com
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM - Yahoo Finance
Redburn Atlantic Initiates BridgeBio Pharma at Buy With $50 Price Target - Marketscreener.com
Redburn-Atlantic sets $50 target for BridgeBio stock with Buy rating - Investing.com India
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Sold by Pictet Asset Management Holding SA - MarketBeat
Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey
(BBIO) Technical Data - news.stocktradersdaily.com
BridgeBio Pharma CEO sells $2.76 million in stock By Investing.com - Investing.com Canada
BridgeBio Pharma CEO sells $2.76 million in stock - Investing.com India
Japan approves new ATTR-CM treatment Beyonttra By Investing.com - Investing.com South Africa
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug - Benzinga
Genmab and BridgeBio Pharma announce Japan approval for their treatments - Seeking Alpha
BridgeBio’s Beyonttra approved in Japan - The Pharma Letter
BridgeBio Pharma Says Beyonttra Approved in Japan to Treat Heart Condition - Marketscreener.com
BridgeBio Announces Approval Of Beyonttra In Japan; To Receive $30 Mln Milestone Payment - Nasdaq
Beyonttra(TM) (Acoramidis), The First Near-Complete TTR Stabilizer (>=90%), Approved in Japan To Treat ATTR-CM - Marketscreener.com
Japan approves new ATTR-CM treatment Beyonttra - Investing.com
Game-Changing Heart Disease Drug Beyonttra Achieves 42% Mortality Reduction in Japan - Stock Titan
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions - The Manila Times
BridgeBio Pharma to Present Cardiovascular Outcomes Data from ATTRibute-CM Study at ACC Annual Scientific Sessions 2025 - Nasdaq
Achondroplasia Treatment Market Size in 7MM is expected to grow - openPR
Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug - MSN
BridgeBio Pharma Inc (BBIO) Announces Equity Grants to New Employees - GuruFocus.com
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bridgebio Pharma reports inducement grants under Nasdaq listing rule 5635(C)(4) -March 21, 2025 at 04:05 pm EDT - Marketscreener.com
Alnylam Drug Approval Brings Cardiomyopathy Competition to Pfizer, BridgeBio Pharma - MedCity News
Alnylam prices heart drug at premium to rivals - BioPharma Dive
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio - MSN
NYSE Content advisory: Pre-Market update + Stocks try for weekly gains - The Globe and Mail
BridgeBio, Editas finance chiefs depart; Former FDA No. 2 joins Recursion’s board - Endpoints News
Alnylam Joins Competitive ATTR-CM Market With Amvuttra Approval - News & Insights
Achondroplasia Market on Track for Major Expansion by 2034, - openPR
UBS Adjusts Price Target on BridgeBio Pharma to $65 From $62, Maintains Buy Rating - Marketscreener.com
Trend Tracker for (BBIO) - Stock Traders Daily
BridgeBio Announces CFO Succession - The Manila Times
BridgeBio Pharma Appoints New President and CFO - TipRanks
BridgeBio Pharma announces CFO succession -March 17, 2025 at 04:30 pm EDT - Marketscreener.com
BridgeBio Pharma Names New CFO -March 17, 2025 at 04:21 pm EDT - Marketscreener.com
BridgeBio Promotes Internal Leader to CFO Role, Ensuring Strategic Continuity - StockTitan
BridgeBio Pharma Names Thomas Trimarch as New Finance Chief - MarketWatch
Lobbying Update: $30,000 of BRIDGEBIO PHARMA INC. lobbying was just disclosed - Nasdaq
BridgeBio Pharma’s SWOT analysis: innovative pipeline drives stock potential - Investing.com
BridgeBio Pharma director Hannah Valantine sells $419,499 in stock By Investing.com - Investing.com South Africa
BridgeBio Pharma director Hannah Valantine sells $419,499 in stock - Investing.com
Genetic Disorder L.P. Kkr Sells 6,000,000 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock - Defense World
Kkr sells $197.76 million in BridgeBio Pharma stock By Investing.com - Investing.com Australia
(BBIO) On The My Stocks Page - Stock Traders Daily
Major Stakeholder Sells Millions in BridgeBio Pharma Stock! - TipRanks
Kkr sells $197.76 million in BridgeBio Pharma stock - Investing.com
BridgeBio Shares Fall After KKR Genetic Disorder Sells 6 Million Shares -March 06, 2025 at 09:54 am EST - Marketscreener.com
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):